Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy.

Abstract

Although tau pathology, behavioral deficits, and neuronal loss are observed in patients with tauopathies, the relationship between these endpoints has not been clearly established. Here we found that rTg4510 mice, which overexpress human mutant tau in the forebrain, develop progressive age-dependent increases in locomotor activity (LMA), which correlates with neurofibrillary tangle (NFT) pathology, hyperphosphorylated tau levels, and brain atrophy. To further clarify the relationship between these endpoints, we treated the rTg4510 mice with either doxycycline to reduce mutant tau expression or an O-GlcNAcase inhibitor Thiamet G, which has been shown to ameliorate tau pathology in animal models. We found that both doxycycline and Thiamet G treatments starting at 2 months of age prevented the progression of hyperactivity, slowed brain atrophy, and reduced brain hyperphosphorylated tau. In contrast, initiating doxycycline treatment at 4 months reduced neither brain hyperphosphorylated tau nor hyperactivity, further confirming the relationship between these measures. Collectively, our results demonstrate a unique behavioral phenotype in the rTg4510 mouse model of tauopathy that strongly correlates with disease progression, and that early interventions which reduce tau pathology ameliorate the progression of the locomotor dysfunction. These findings suggest that better understanding the relationship between locomotor deficits and tau pathology in the rTg4510 model may improve our understanding of the mechanisms underlying behavioral disturbances in patients with tauopathies.

• Authors: Xiaohai Wang, Karen Smith, Michelle Pearson, Anna Hughes, Mali L Cosden, Jacob Marcus, J Fred Hess, Mary J Savage, Thomas Rosahl, Sean M Smith, Joel B Schachter, Jason M Uslaner
• Journal: PloS one (PLoS One) Vol. 13 Issue 4 Pg. e0195486 ( 2018) ISSN: 1932-6203 [Electronic] United States
• PMID: 29624602 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Enzyme Inhibitors
• MAPT protein, human
• Mutant Proteins
• Pyrans
• Recombinant Proteins
• Thiazoles
• tau Proteins
• thiamet G
• hexosaminidase C
• beta-N-Acetylhexosaminidases
• Doxycycline

Topics

• Animals
• Brain (metabolism, pathology)
• Disease Models, Animal
• Disease Progression
• Doxycycline (therapeutic use)
• Enzyme Inhibitors (therapeutic use)
• Gene Expression (drug effects)
• Humans
• Mice
• Mice, 129 Strain
• Mice, Transgenic
• Motor Activity (genetics, physiology)
• Mutant Proteins (genetics, metabolism)
• Neurofibrillary Tangles (pathology)
• Phosphorylation
• Pyrans (therapeutic use)
• Recombinant Proteins (genetics, metabolism)
• Tauopathies (drug therapy, pathology, physiopathology)
• Thiazoles (therapeutic use)
• beta-N-Acetylhexosaminidases (antagonists & inhibitors)
• tau Proteins (genetics, metabolism)